Cynthia Olivia Baldelamar-Juárez

Cynthia Olivia Baldelamar-Juárez

Auto-generated profile, based on publicly available information

Cynthia Olivia Baldelamar-Juárez


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2025 in bioRxiv
Verified
Preprint
Open access
APAaron Pantoja-Angles
Aaron Pantoja-Angles
AZAli Zahir
Ali Zahir
SASherin Abdelrahman
Sherin Abdelrahman
CBCynthia Olivia Baldelamar-Juárez
Cynthia Olivia Baldelamar-Juárez
SCShahid Chaudhary
Shahid Chaudhary
MMMagdy Mahfouz
Magdy Mahfouz
Synthetic biology enables the integration of sophisticated genetic programs into microorganisms, transforming them into potent vehicles for therapeutic applications. Engineering strategies for microorganisms are rapidly evolving, offering promising solutions for cancer therapy, microbiome modulation, digestive health support, and beyond. Developing novel tools to engineer safe, nonpathogenic microbial platforms is essential for advancing clinical therapies. In this work, we present an innovative engineering approach for the probiotic Escherichia coli Nissle (EcN), aimed at creating a safe and efficient chassis for the bioproduction of therapeutics. The EcN endogenous pM1 and pM2 plasmids were cured and re-engineered to introduce a CRISPR-Cas12 chromosome shredding device and a therapeutic-producing genetic circuit, thereby generating a nonproliferative therapeutic-delivery system. Next, we build an AI-based bioinformatic pipeline to predict Anticancer-Cell-Penetrating Peptides (ACCPP) candidates. As a proof-of-concept, a selected ACCPP was produced in the engineered EcN chromosome-shredded (CS) chassis. This strategy yields a robust and controllable platform for the safe production and delivery of therapeutics, paving the way for the future development of microbial therapies and their clinical applications. GRAPHICAL